X4 is focused on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Our first-in-class, oral, small molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. A number of PIs are attributed to the improper trafficking of immune cells related ...
X4 is focused on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Our first-in-class, oral, small molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. A number of PIs are attributed to the improper trafficking of immune cells related to the CXCR4 receptor and its ligand CXCL12.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.